For AML patients, one gene may make a big difference.

Printed from https://www.cancerquest.org/newsroom/2010/11/aml-patients-one-gene-may-make-big-difference on 12/15/2025



Sequencing of DNA from 281 acute myeloid leukemia (AML) patients has identified a single gene that is associated with a worse prognosis. The gene, *DNMT3A*, encodes a DNA methyltransferase, an enzyme that modifies DNA. Patients with mutations in *DNMT3A* had a median survival of 12.3 months vs 41.1 months for those who did not have a mutated gene. The study may lead to more aggressive treatment plans for patients with changes in *DNMT3A*.

Source

http://www.nejm.org/doi/full/10.1056/NEJMoa1005143 Learn More Learn More